MedTrace Logo

Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)

NCT05845489 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 11086

Last updated 2025-12-31

No results posted yet for this study

Summary

The investigators will evaluate the efficacy and safety of clopidogrel for primary prevention in patients diagnosed with coronary atherosclerosis on imaging that did not require revascularization therapy.

The trial will test the hypothesis that clopidogrel is beneficial in preventing major adverse cardiovascular and cerebrovascular events (MACCE) in patients with subclinical coronary atherosclerosis identified on imaging.

Conditions

Interventions

DRUG

Clopidogrel treatment group

Patients assigned to the clopidogrel treatment group will maintain clopidogrel 75mg once a day for at least 5 years.

OTHER

No antiplatelet or anticoagulant group

Patients assigned to the no antiplatelet or anticoagulant group will not prescribe antithrombotics for at least 5 years. However, when there is a medical need for antithrombotic therapy during the follow-up, the prescription of antithrombotics is permitted with reporting to the research board.

Sponsors & Collaborators

  • Samjin Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • CKD Pharmaceutical Limited

    collaborator UNKNOWN

  • Hanmi Pharmaceutical co., ltd.

    collaborator OTHER

  • Yuhan Pharmaceutical Company

    collaborator UNKNOWN

  • Daewoong Pharmaceutical Co. LTD.

    collaborator INDUSTRY

  • Dong-A ST Co., Ltd.

    collaborator INDUSTRY

  • IlDong Pharmaceutical Co Ltd

    collaborator INDUSTRY

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Hyo-Soo Kim, MD, PhD · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-22
Primary Completion
2028-12-31
Completion
2031-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05845489 on ClinicalTrials.gov